Strategy Asset Managers LLC lessened its stake in shares of Eli Lilly And Co (NYSE:LLY) by 60.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,763 shares of the company’s stock after selling 13,118 shares during the quarter. Strategy Asset Managers LLC’s holdings in Eli Lilly And Co were worth $971,000 at the end of the most recent quarter.
Several other institutional investors also recently added to or reduced their stakes in the company. Meridian Wealth Management LLC purchased a new position in Eli Lilly And Co in the first quarter worth $38,000. Manchester Financial Inc. purchased a new position in Eli Lilly And Co in the second quarter worth $40,000. Litman Gregory Asset Management LLC purchased a new position in Eli Lilly And Co in the second quarter worth $47,000. Personal Wealth Partners purchased a new position in Eli Lilly And Co in the second quarter worth $53,000. Finally, Kavar Capital Partners LLC purchased a new position in Eli Lilly And Co in the second quarter worth $55,000. Institutional investors and hedge funds own 76.72% of the company’s stock.
Shares of LLY stock traded down $0.65 during mid-day trading on Monday, reaching $110.24. The stock had a trading volume of 1,057,561 shares, compared to its average volume of 3,110,068. Eli Lilly And Co has a 12-month low of $104.17 and a 12-month high of $132.13. The company has a market cap of $107.62 billion, a P/E ratio of 19.86, a price-to-earnings-growth ratio of 1.93 and a beta of 0.16. The business has a 50-day simple moving average of $111.57 and a 200 day simple moving average of $116.87. The company has a current ratio of 1.13, a quick ratio of 0.87 and a debt-to-equity ratio of 4.98.
Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings results on Tuesday, July 30th. The company reported $1.50 earnings per share for the quarter, beating analysts’ consensus estimates of $1.45 by $0.05. The business had revenue of $5.64 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Eli Lilly And Co had a return on equity of 70.86% and a net margin of 33.76%. The business’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter last year, the business posted $1.48 earnings per share. Research analysts anticipate that Eli Lilly And Co will post 5.73 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Thursday, August 15th were paid a dividend of $0.645 per share. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.34%. The ex-dividend date of this dividend was Wednesday, August 14th. Eli Lilly And Co’s payout ratio is currently 46.49%.
Several research analysts have issued reports on LLY shares. Goldman Sachs Group started coverage on Eli Lilly And Co in a research report on Tuesday, May 28th. They issued a “buy” rating and a $135.00 price objective for the company. Zacks Investment Research cut Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday, May 21st. Bank of America set a $120.00 price target on Eli Lilly And Co and gave the company a “neutral” rating in a research report on Tuesday, September 10th. Finally, ValuEngine cut Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Friday, June 28th. Nine analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $122.93.
In related news, SVP Stephen F. Fry sold 9,452 shares of the stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $115.00, for a total transaction of $1,086,980.00. Following the sale, the senior vice president now owns 100,211 shares of the company’s stock, valued at $11,524,265. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Alfonso G. Zulueta sold 19,500 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $112.91, for a total value of $2,201,745.00. Following the sale, the senior vice president now directly owns 38,306 shares in the company, valued at approximately $4,325,130.46. The disclosure for this sale can be found here. 0.11% of the stock is owned by company insiders.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Article: What is a Backdoor Roth IRA?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.